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AlthoughZygomycetescauselife-threatening,opportunisticinfectionsinimmunocompromisedhosts,thefirstcase
of vaginitis caused by Mucor species in a healthy woman is reported. Mucor vaginitis, which causedmild symptoms
only, was refractory to conventional azole therapy and resistant to flucytosine. Cure was achieved with topical
amphotericin B.
Key words: VAGINITIS, FUNGAL INFECTION, AMPHOTERICIN B
Infect Dis Obstet Gynecol 2001;9:117–118
Correspondenceto:J. D.Sobel,MD,Division ofInfectiousDiseases,4Brush,HarperUniversity Hospital,3990JohnR,Detroit,
MI 48201. E-mail: Jsobel@intmed.wayne.edu
Gynecologic case report 117
The vast majority of vaginal fungal infections are
caused by Candida species, especially Candida
albicans1,2. Recently, attention has focused on an
unconfirmed increase in vaginal infections caused
by C. glabrata3. Most microbiological investiga-
tions of large numbers of women with fungal
vaginitis have reported infrequent symptomatic
vaginitis caused by unusual species of Candida
including C. tropicalis, C. parapsilosis, and C.
krusei1,3. Rarely, vaginitis caused by Saccharomyces
cerevisiae has been reported4. Although the
Zygomycetes class of microorganisms are recog-
nizedas majorpathogensinimmunocompromised
hosts, no mention in the literature has been
made of vaginitis caused by these opportunistic
pathogens5.
CASE HISTORY
A 56-year-old female was referred because of
vulvovaginal symptoms that had begun approxi-
mately 18 months previously, consisting pre-
dominantly of a stinging sensation in the vulva.
Other symptoms included vulvovaginal itching,
soreness, and discomfort. Because of chronic
symptomsandpositive10%KOHmicroscopy,she
had received repeated courses of topical
(miconazole, clotrimazole and terconazole) and
systemic azoles (fluconazole) as well as topical
boric acid without any relief. On one occasion, a
fungalculture obtained was positive for Mucor spe-
cies. She had no abnormal discharge or
dyspareunia and her husband was asymptomatic.
Prior to the onset of symptoms, she had repeated
attacksof bacterial cystitis, treated with antibiotics.
Her past medical history was significant only for
interstitial cystitis.
Examination demonstrated normal appearance
of vulva and vestibule. The vagina containedfairly
copious, pasty white discharge, which was not
malodorous and was otherwise normal; the cervix
was normal. Laboratory tests showed a vaginal pH
of 4.2 with a negative amine test. Saline micro-
scopy revealed large numbers of atypical blasto-
condia and broad, non-septate hyphae branching
at irregular intervals. A 10% KOH examination
revealed large numbers of blastocondiaand hyphal
elements consistent with Zygomycetes. Definitive
diagnosis was established by culture, which
showed Mucor indicus species. In vitro susceptibility
testsshowedthatthevaginal isolatewassensitive to
amphotericin B and resistant to flucytosine,
imidazoles and triazoles. She was placed on topical
therapy with 3% amphotericin B cream 5 g dailyfor 3 weeks. After an initial clinical response to
amphotericin B, she had a relapse with minimal
symptoms and culturesremained positive. Shewas
retreated with 4 additional weeks of topical
amphotericin B and then placed on a tapering
alternate day dose for 2 months. Her symptoms of
stinging and itching resolved and she has remained
culture-negative and asymptomatic for a further
12-month follow-up period.
COMMENTS
Mucormycosis is a rare but commonly fatal
invasive fungal infection caused by one of the
ubiquitous saprophytic fungi of the Zygomycetes
class. Species of the Rhizopus, Mucor, and Absidia
genera ofthe Mucoraceae family are the organisms
most commonly isolated5,6. Mucormycosis is
known to affect patients who are immuno-
compromised and usually neutropenic, and those
with uncontrolled diabetes mellitus and keto-
acidosis6. Other risk factors include iron overload,
desferrioxamine administration, wound contami-
nation with soil, colonized adhesive tape, cortico-
steroid use and severe protein calorie malnutrition.
Clinical features depend upon the organ involved
and most commonly involve paranasal sinuses and
lungs and less commonly the gastrointestinal
tract7. There are few reports of genitourinary
mucormycosis in the literature. Genitourinary
involvement is predominantly of the kidneys and
has been found with systemic dissemination8.
Parenteral high-dose amphotericin B is the most
effective treatment.No case ofvaginalinfection by
Zygomycetes has been published to date.
The lack of response in the reported patient to
treatment with topical azoles is not surprising,
sincetheseagentsareinactiveagainstM.indicusand
the Mucoraceae in general. Similarly, flucytosine,
which is useful in eliminating azole-resistant
C. glabrata, has no activity in vitro against
Zygomycetes. Amphotericin B remains the main-
stay of therapy in life-threatening mucormycosis,
buthas been used extremely infrequentlyas a topi-
cal agent for vaginal mycotic infections and is not
available commercially for this indication. A 3%
concentrationwasusedsomewhatarbitrarily,since
this concentration is used to treat oropharyngeal
candidiasis due to sensitive Candida species.
Response in the reported case was not dramatic
and required retreatment and extension of the
treatment duration. The pathogenesis of this
obscureinfectionremains anenigma andcouldnot
be correlated with any personal habits (douching)
or other risk factors. This unusual and obstinate
case emphasizes the value of obtaining vaginal
fungal cultures in treatment of unresponsive cases,
as well as the need for full identification of the iso-
lated pathogenand basingtherapyon susceptibility
testing.
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